Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

CBLB-612

Alternative Names: cblb-612, cblb612, cblb 612
Latest Update: 2016-07-20
Latest Update Note: Clinical Trial Update

Product Description

for neutropenia prophylaxis in breast cancer patients receiving doxorubicin and cyclophosphamide myelosuppressive chemotherapy

Mechanisms of Action: TLR2 Agonist

Novel Mechanism: Yes

Modality: Cell Therapy

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: BioLab 612
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Breast Cancer|Neutropenia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
BL-612-BC1

P2

Completed

Neutropenia|Breast Cancer

2016-07-01

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions